Clinical trial NCT00240344: Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal
Official title: REALISTIC: Protocol for an Observational Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New EAS LDL-C Target Goal
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercholesterolemia
Keywords: High risk patients
Crestor
Rosuvastatin
LDL cholesterol
observational
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-10-18
Enrollment: 2650
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primary care

Brief summary: The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.


Eligibility criteria: Inclusion Criteria:

* High risk patients
* High doses of other statins
* LDL-C known, starts with Crestor 10 mg
* Permission to use patient data by AstraZeneca (AZ)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Alkmaar
country: Netherlands
facility: Research Site
city: Almelo
country: Netherlands
facility: Research Site
city: Alphen Aan Den Rijn
country: Netherlands
facility: Research Site
city: Amsterdam
country: Netherlands
facility: Research Site
city: Apeldoorn
country: Netherlands
facility: Research Site
city: Assen
country: Netherlands
facility: Research Site
city: Bergen Op Zoom
country: Netherlands
facility: Research Site
city: Beverwijk
country: Netherlands
facility: Research Site
city: Bilthoven
country: Netherlands
facility: Research Site
city: Blaricum
country: Netherlands
facility: Research Site
city: Boxmeer
country: Netherlands
facility: Research Site
city: Breda
country: Netherlands
facility: Research Site
city: Brunssum
country: Netherlands
facility: Research Site
city: Capelle Aan Den Ijssel
country: Netherlands
facility: Research Site
city: Delft
country: Netherlands
facility: Research Site
city: Delfzijl
country: Netherlands
facility: Research Site
city: Den Helder
country: Netherlands
facility: Research Site
city: Dirksland
country: Netherlands
facility: Research Site
city: Doetinchem
country: Netherlands
facility: Research Site
city: Dokkum
country: Netherlands
facility: Research Site
city: Dordrecht
country: Netherlands
facility: Research Site
city: Drachten
country: Netherlands
facility: Research Site
city: Ede Gld
country: Netherlands
facility: Research Site
city: Eindhoven
country: Netherlands
facility: Research Site
city: Emmen
country: Netherlands
facility: Research Site
city: Enschede
country: Netherlands
facility: Research Site
city: Etten-leur
country: Netherlands
facility: Research Site
city: Geldrop
country: Netherlands
facility: Research Site
city: Gouda
country: Netherlands
facility: Research Site
city: Groningen
country: Netherlands
facility: Research Site
city: Haarlem
country: Netherlands
facility: Research Site
city: Hardenberg
country: Netherlands
facility: Research Site
city: Heerenveen
country: Netherlands
facility: Research Site
city: Heerlen
country: Netherlands
facility: Research Site
city: Helmond
country: Netherlands
facility: Research Site
city: Hengelo Ov
country: Netherlands
facility: Research Site
city: Hoofddorp
country: Netherlands
facility: Research Site
city: Hoogeveen
country: Netherlands
facility: Research Site
city: Hoorn Nh
country: Netherlands
facility: Research Site
city: Ijmuiden
country: Netherlands
facility: Research Site
city: Landsmeer
country: Netherlands
facility: Research Site
city: Leiden
country: Netherlands
facility: Research Site
city: Lelystad
country: Netherlands
facility: Research Site
city: Maastricht
country: Netherlands
facility: Research Site
city: Meppel
country: Netherlands
facility: Research Site
city: Oosterhout Nb
country: Netherlands
facility: Research Site
city: OSS
country: Netherlands
facility: Research Site
city: Purmerend
country: Netherlands
facility: Research Site
city: Roermond
country: Netherlands
facility: Research Site
city: Roosendaal
country: Netherlands
facility: Research Site
city: Rotterdam
country: Netherlands
facility: Research Site
city: S-gravenhage
country: Netherlands
facility: Research Site
city: S-hertogenbosch
country: Netherlands
facility: Research Site
city: Schiedam
country: Netherlands
facility: Research Site
city: Sneek
country: Netherlands
facility: Research Site
city: Spijkenisse
country: Netherlands
facility: Research Site
city: Stadskanaal
country: Netherlands
facility: Research Site
city: Terneuzen
country: Netherlands
facility: Research Site
city: Tiel
country: Netherlands
facility: Research Site
city: Tilburg
country: Netherlands
facility: Research Site
city: Utrecht
country: Netherlands
facility: Research Site
city: Veghel
country: Netherlands
facility: Research Site
city: Veldhoven
country: Netherlands
facility: Research Site
city: Venlo
country: Netherlands
facility: Research Site
city: Vlaardingen
country: Netherlands
facility: Research Site
city: Vlissingen
country: Netherlands
facility: Research Site
city: Waalwijk
country: Netherlands
facility: Research Site
city: Weert
country: Netherlands
facility: Research Site
city: Winschoten
country: Netherlands
facility: Research Site
city: Winterswijk
country: Netherlands
facility: Research Site
city: Zaandam
country: Netherlands
facility: Research Site
city: Zevenaar
country: Netherlands
facility: Research Site
city: Zoetermeer
country: Netherlands
facility: Research Site
city: Zutphen
country: Netherlands
facility: Research Site
city: Zwolle
country: Netherlands
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: AstraZeneca Netherlands Medical Director, MD
role: STUDY_DIRECTOR
References: